Actionable news
0
All posts from Actionable news
Actionable news in TSRO: TESARO, Inc.,

TESARO Announces Submission of Investigational New Drug Application for Anti-TIM-3 Antibody TSR-022 to the U.S. FDA

WALTHAM, Mass., Apr 25, 2016 (GLOBE NEWSWIRE via COMTEX) --

TESARO, Inc. TSRO, +6.07% an oncology-focused biopharmaceutical company, today announced the submission of an Investigational New Drug (IND) Application for TSR-022 to the U.S. Food and Drug Administration. TSR-022 is a monoclonal antibody drug candidate targeting TIM-3.

"TSR-022 is poised to be the second antibody candidate from our immuno-oncology portfolio to begin clinical studies," said Mary Lynne Hedley, Ph.D., President and COO of TESARO. "Following clearance of the IND, we plan to begin a Phase 1 study in mid-2016."

About TSR-022TSR-022 is a monoclonal antibody candidate targeting TIM-3 and was developed as part of a collaboration between TESARO and AnaptysBio, Inc. This collaboration was initiated in March of 2014, and is focused on the development of monospecific antibody drug candidates targeting PD-1 (TSR-042), TIM-3 (TSR-022), and LAG-3, and bi-specific antibody drug candidates targeting PD-1/TIM-3 and PD-1/LAG-3, in...


More